These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34840268)

  • 1. Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors.
    Wingler LM; Feld AP
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):342-353. PubMed ID: 34840268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies detecting and modulating GPCRs outside in and inside out.
    Heukers R; De Groof TWM; Smit MJ
    Curr Opin Cell Biol; 2019 Apr; 57():115-122. PubMed ID: 30849632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.
    Mujić-Delić A; de Wit RH; Verkaar F; Smit MJ
    Trends Pharmacol Sci; 2014 May; 35(5):247-55. PubMed ID: 24690241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.
    De Groof TWM; Bobkov V; Heukers R; Smit MJ
    Mol Cell Endocrinol; 2019 Mar; 484():15-24. PubMed ID: 30690070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Nanobodies on G Protein-Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents.
    Salom D; Wu A; Liu CC; Palczewski K
    Mol Pharmacol; 2024 Sep; 106(4):155-163. PubMed ID: 39107078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobodies to Study G Protein-Coupled Receptor Structure and Function.
    Manglik A; Kobilka BK; Steyaert J
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():19-37. PubMed ID: 27959623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobodies as sensors of GPCR activation and signaling.
    El Daibani A; Che T
    Methods Cell Biol; 2021; 166():161-177. PubMed ID: 34752331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies.
    Schlimgen RR; Peterson FC; Heukers R; Smit MJ; McCorvy JD; Volkman BF
    Nat Commun; 2024 May; 15(1):4611. PubMed ID: 38816420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryo-EM advances in GPCR structure determination.
    Shihoya W; Iwama A; Sano FK; Nureki O
    J Biochem; 2024 Jul; 176(1):1-10. PubMed ID: 38498911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobodies and their Use in GPCR Drug Discovery.
    Cromie KD; Van Heeke G; Boutton C
    Curr Top Med Chem; 2015; 15(24):2543-57. PubMed ID: 26126902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.
    Ayoub MA; Crépieux P; Koglin M; Parmentier M; Pin JP; Poupon A; Reiter E; Smit M; Steyaert J; Watier H; Wilkinson T
    MAbs; 2017 Jul; 9(5):735-741. PubMed ID: 28475474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SNAP-Tagged Nanobodies Enable Reversible Optical Control of a G Protein-Coupled Receptor via a Remotely Tethered Photoswitchable Ligand.
    Farrants H; Gutzeit VA; Acosta-Ruiz A; Trauner D; Johnsson K; Levitz J; Broichhagen J
    ACS Chem Biol; 2018 Sep; 13(9):2682-2688. PubMed ID: 30141622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yeast surface display platform for rapid discovery of conformationally selective nanobodies.
    McMahon C; Baier AS; Pascolutti R; Wegrecki M; Zheng S; Ong JX; Erlandson SC; Hilger D; Rasmussen SGF; Ring AM; Manglik A; Kruse AC
    Nat Struct Mol Biol; 2018 Mar; 25(3):289-296. PubMed ID: 29434346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of nanobodies targeting GPCR.
    Zhang S; Fan Z; Liu J
    Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
    Saleh N; Ibrahim P; Clark T
    Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDX-MS-optimized approach to characterize nanobodies as tools for biochemical and structural studies of class IB phosphoinositide 3-kinases.
    Rathinaswamy MK; Fleming KD; Dalwadi U; Pardon E; Harris NJ; Yip CK; Steyaert J; Burke JE
    Structure; 2021 Dec; 29(12):1371-1381.e6. PubMed ID: 34348129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NanoB
    van den Bor J; Bergkamp ND; Anbuhl SM; Dekker F; Comez D; Perez Almeria CV; Bosma R; White CW; Kilpatrick LE; Hill SJ; Siderius M; Smit MJ; Heukers R
    Cell Rep Methods; 2023 Mar; 3(3):100422. PubMed ID: 37056381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobody-enabled monitoring of kappa opioid receptor states.
    Che T; English J; Krumm BE; Kim K; Pardon E; Olsen RHJ; Wang S; Zhang S; Diberto JF; Sciaky N; Carroll FI; Steyaert J; Wacker D; Roth BL
    Nat Commun; 2020 Mar; 11(1):1145. PubMed ID: 32123179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody fragments for stabilization and crystallization of G protein-coupled receptors and their signaling complexes.
    Shukla AK; Gupta C; Srivastava A; Jaiman D
    Methods Enzymol; 2015; 557():247-58. PubMed ID: 25950968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modular transient nanoclustering of activated β2-adrenergic receptors revealed by single-molecule tracking of conformation-specific nanobodies.
    Gormal RS; Padmanabhan P; Kasula R; Bademosi AT; Coakley S; Giacomotto J; Blum A; Joensuu M; Wallis TP; Lo HP; Budnar S; Rae J; Ferguson C; Bastiani M; Thomas WG; Pardon E; Steyaert J; Yap AS; Goodhill GJ; Hilliard MA; Parton RG; Meunier FA
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30476-30487. PubMed ID: 33214152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.